A Sensory Neuron-expressed Interleukin-31 Receptor Mediates T helper Cell-dependent Itch: Involvement of TRPV1 and TRPA1

Ferda Cevikbas, PhD1,5,*; Xidao Wang, PhD2,†; Tasuku Akiyama, PhD3; Cordula Kempkes, PhD1; Terhi Savinko, PhD4; Attila Antal, MD5; Gabriela Kukova, MD5; Timo Buhl, MD1; Akihiko Ikoma, MD, PhD1; Joerg Buddenkotte, PhD6; Vassili Soumelis, MD7; Micha Feld, PhD5; Harri Alenius, PhD4; Stacey R. Dillon, PhD8; Earl Carstens, PhD3; Bernhard Homey, MD5,§; Allan Basbaum, PhD2,*,§; and Martin Steinhoff, MD, PhD1,5,*,§

1Depts. of Dermatology and Surgery, University of California San Francisco, San Francisco, CA, USA 2Depts. of Anatomy and W.M. Keck Foundation Center for Integrative Neuroscience, University California San Francisco, San Francisco, CA, USA 3Dept. of Neurobiology, University California Davis, CA, USA 4Unit of Toxicology, Finnish Institute of Occupational Health, Helsinki, Finland 5Dept. of Dermatology, University Hospital Duesseldorf, Duesseldorf, Germany 6Dept. of Dermatology, University Hospital Muenster, Muenster Germany 7Dep. of Immunology, Institut Curie, Paris, France 8ZymoGenetics, Inc. (a Bristol-Myers Squibb Company) Seattle, WA, USA

Abstract

Background—Although the cytokine, interleukin-31 (IL-31), has been implicated in inflammatory and lymphoma-associated itch, the cellular basis for its pruritic action is yet unclear.

Objective—To determine whether immune cell-derived IL-31 directly stimulates sensory neurons, and to identify the molecular basis of IL-31-induced itch.

Methods—We used immunohistochemistry and qRT-PCR to determine IL-31 expression levels in mice and humans. Immunohistochemistry, immunofluorescence, qRT-PCR, in vivo pharmacology, western blotting, single cell calcium and electrophysiology were used to examine...
the distribution, functionality and cellular basis of the neuronal IL-31 receptor (IL-31RA) in mice and humans.

Results—Among all immune and resident skin cells examined, IL-31 was predominantly produced by Th2 and to a significantly lesser extend by mature dendritic cells. Cutaneous and intrathecal injections of IL-31 evoked intense itch, and its concentration increased significantly in murine atopic-like dermatitis skin. Both human and mouse DRG neurons express IL-31RA, largely in neurons that co-express TRPV1. IL-31-induced itch was significantly reduced in TRPV1- and TRPA1-deficient mice, not c-kit or PAR-2 mice. In cultured primary sensory neurons, IL-31 triggered Ca\textsuperscript{2+}-release and ERK1/2 phosphorylation, Inhibition of which blocked IL-31 signaling \textit{in vitro} and reduced IL-31-induced scratching \textit{in vivo}.

Conclusion—IL-31RA is a functional receptor expressed by a small subpopulation of IL-31RA\textsuperscript{+}/TRPV1\textsuperscript{+}/TRPA1\textsuperscript{+} neurons, and is a critical neuro-immune link between Th2 cells and sensory nerves for the generation of T cell-mediated itch. Thus, targeting neuronal IL-31RA may be effective in the management of Th2-mediated itch, including atopic dermatitis and cutaneous T cell lymphoma.

Keywords
cytokine; atopic dermatitis; sensory nerve; skin; TRP channel

Introduction

Cytokines are critical contributors to various inflammatory skin diseases and cutaneous malignancies that are also pruritic, notably atopic dermatitis (AD) and cutaneous T cell lymphoma \textsuperscript{1–4}. How cytokines exert their pruritic effects and the extent to which there is direct or indirect involvement of sensory nerves that express specific cytokine receptors is currently unclear. Because many inflammatory and malignant pruritic skin diseases have an associated Th2 cell signature, analysis of the interplay between Th2 cells and sensory neurons will significantly enhance our understanding of the mechanisms underlying the communication between the adaptive immune and the nervous system to induce itch, and therefore how to treat recalcitrant itch in humans.

Interleukin-31 (IL-31), a Th2-cell-derived cytokine, is increased in pruritic atopic skin and cutaneous T cell lymphoma in humans \textsuperscript{3–7} and induces severe pruritic atopic-like dermatitis (AD-like) in an IL-31 transgenic mouse model \textsuperscript{5}. Moreover, neutralization of IL-31 in NC/Nga mice, an AD-like mouse model, reduced scratching and improved wound healing \textsuperscript{8}. IL-31 binds to a IL31RA, which exists as a short, non-signaling/inhibitory, or a long signaling subunit \textsuperscript{9}. To date, no long or short form of the IL31-RA has been described in mice.

Although IL-31RA is expressed in murine neuronal tissue \textsuperscript{10}, detailed information about the neuro-immune link and functional relevance of IL-31RA\textsuperscript{+} neurons is lacking.

Recent studies focused on the function of sensory neurons in itch \textsuperscript{11–13}. Thus far, TRPV1\textsuperscript{+} and a subpopulation of TRPV1\textsuperscript{+}/TRPA1\textsuperscript{+} sensory neurons have been implicated to be required for pruritogen-induced itch signaling \textsuperscript{14–18}. Whether cytokine-induced itch has a comparable neuronal basis is unknown. Therefore, the aim of our study was determine the cellular basis of IL-31-induced itch.
Results

Production of IL-31 by human T$_{H2}$ helper cells

Several studies demonstrated IL-31 is expressed by skin-homing T$_{H2}$ cells during inflammation, most notably in AD. No study has systematically compared expression levels of IL-31 in all potentially relevant immune and permanent skin cells involved in AD. Using qPCR, we compared expression levels of IL-31 and its receptor IL-31RA in various immune and permanent skin cells of patients with atopic dermatitis and psoriasis. Skin specimen were obtained from healthy donors (n=35), AD patients (non-lesional n=13, lesional n=50), and psoriasis patients (non-lesional n=14, lesional n=49).

IL-31 mRNA transcript was increased (approx. 4-fold) in lesional skin of AD compared to non-lesional or healthy skin (Fig 1a). Lesional AD skin showed significantly higher levels of IL-31RA long isoform compared to healthy skin (Fig. 1a, p<0.001), while no statistical differences were observed for the inhibitory short isoform, which was largely expressed in healthy skin. In psoriasis, IL-31RA long was also upregulated but to a lesser extent as in lesional AD skin. Of note, while IL-31 was significantly upregulated in AD, this was not the case for psoriasis. Compared to AD, neither lesional nor non-lesional psoriasis specimens showed upregulation of either subforms. OSMR-β was equally expressed in all examined samples (Fig. 1a). We next co-localized IL-31 (green) with skin-infiltrating CLA$^+$ cells (red) in human lesional AD skin (Fig. 1b, colocalization, yellow cells and arrows). As expected in AD, T$_{H2}$ cells were found almost exclusively in the dermis. Quantitative analysis of immunofluorescence revealed that 62 ±/− 8.2% of skin-homing CRTH2$^+$ T$_{H2}$ cells to be positive for IL-31 (n≥10 patients per group).

Next, we used qPCR from isolated human T cell subtypes to compare IL-31 mRNA expression in the subsets of T cells and found that IL-31 was predominantly expressed by T$_{H2}$ cells and derives very unlikely from T$_{H0}$, T$_{H1}$ or T$_{H17}$ cells (Fig. 1c). We did not detect IL-31 mRNA in other immune or resident skin cells (keratinocytes, endothelium, fibroblasts) (Fig. 1d). The only other source in human skin appears to be mature dendritic cells, albeit at significantly lower levels compared to T$_{H2}$ cells (appr. 100-fold, Fig. 1d). Therefore, we identified T$_{H2}$ cells as the major, if not exclusive, source of IL-31 in human atopic skin. Whether mature dendritic cells can also generate physiologically relevant quantities of IL-31 in certain diseases is unknown.

Human dorsal root ganglia express IL-31RA

Given the importance of IL-31 in pruritic skin diseases and the detection of IL-31RA mRNA in human skin, we next used immunohistochemistry to analyze the distribution of IL-31RA in DRG neurons obtained from human cadaver (Fig. 1e). We found 50.6% of small-diameter DRG neurons (<30 μM) were IL-31RA$^+$ while all large diameter DRG neurons (>50μM) were IL-31RA$^-$. Preabsorption control verifies specificity of the IL-31RA staining in human DRG (Fig. 1f).

Upregulation of IL-31 in murine atopic-like dermatitis

We used topical application of superantigen Staphylococcus aureus enterotoxin B (SEB) to produce an AD-like phenotype in mice (Fig. 2a) 7, 21. The inflammatory infiltrate consisted of high numbers of CD3$^+$ T cells (Fig. 2c) and eosinophils (Fig. 2d), comparable to human AD. IL-31 mRNA was significantly upregulated in the skin of SEB-treated mice compared to vehicle-treated mice (Fig. 2e). IL-4, a second T$_{H2}$-associated cytokine, was also significantly upregulated in the skin (p<0.001) after SEB treatment (Fig. 2f). In a second AD-like model, we used ovalbumin (OVA) (Supplementary Fig. 1a-d), and also observed upregulation of IL-31 and IL-4, as observed in the SEB model. Thus, IL-31 in...
both human AD and AD-like mouse models derives from cutaneous TH2 cells and may activate IL-31RA on sensory nerves.

**Intradermal IL-31 induces itch, but not pain in murine skin**

The underlying mechanism of IL-31-induced itch and effects of IL-31 on itch versus pain have not been studied as of yet. Figure 3a illustrates that IL-31 produces dose-dependent scratching after intradermal injection into the nape of neck (50±6.89 bouts/30 min with 1.575 nmol/40 μl, 90.67±10.36 bouts/30 min with 3.15 nmol/40 μl and 121.1±12.79 bouts/30 min with 6.3 nmol/40 μl); vehicle: produced only 15.2±1.2 bouts/30 min, p<0.0001.

Intraplantar hindpaw injection (Fig. 3b) of IL-31 (3.15 nmol/5 μl) evoked profound paw licking (156.2±11.39 sec/30 min vs. 22.6±4.55 sec/30 min with vehicle; p<0.0001). IL-31 injection into the cheek 24, 25 (Fig. 3c) provoked robust scratching (100.4±4.16 bouts/30 min for 3.15 nmol/10 μl and 132.4±8.13 bouts/30 min for 6.3 nmol/10 μl vs. 18.8±6.4 bouts/30 min for vehicle, p<0.002). No differences were obtained for IL-31-induced wiping behavior compared to control (8.25±6.93 bouts/30 min, 3.15 nmol/10 μl IL-31 vs. 4.25±3.84 bouts/30 min vehicle) (Fig. 3d). As expected, capsaicin (a positive control for a painful stimulus) evoked significant wiping (54.25±5.32, 10 μg/10 μl) (Fig. 3d).

**Intrathecal IL-31 evokes itch in mice**

We next asked whether itch can be provoked with an approach that bypasses the skin (Fig 3a-c). To assess a possible direct action on CNS circuitry, including the central terminals of primary afferents, we injected IL-31 intrathecally (i.t, directly into the cerebrospinal fluid) at the lumbar level in mice, which induced caudally directed scratching (Fig. 3e). This was dose-dependent, ranging from 69.83±4.47 bouts/30 min for 6.3 fmol/5 μl and 152.3±17.63 bouts/30 min for 6.3 pmol/5 μl; p<0.0001). These findings suggest that IL-31 can induce itch by directly targeting spinal cord circuits, including the central terminals of primary afferents.

**IL-31RA is localized in TRPV1+ peptidergic murine DRG neurons**

We used immunohistochemistry to localize IL-31RA in the DRG, trigeminal ganglion (TG) and SC. Consistent with our results from human DRG (Fig 1e), we found IL31RA immunoreactivity predominantly in small- to medium-sized diameter murine DRG neurons (Fig. 4a), equivalent to about 3.4 % of the total neuron population; expression in the TG was comparable (Supplementary Fig. 3). Importantly, there is complete coexpression of IL-31RA and TRPV1, a marker for capsaicin-responsive, peptidergic DRG neurons (Fig. 4a). However, only 16.2±0.7% of TRPV1+ neurons are IL-31RA+ and 6.7±0.4% bound the lectin IB4, which marks the non-peptidergic subpopulation of unmyelinated sensory neurons (Fig. 4b). We found no overlap of IL-31RA+ neurons with N52 (a marker of cell bodies with myelinated axons; Fig. 4c). In the SC (Fig. 4d), we found a complete overlap of IL-31RA and TRPV1 in axon terminals, and no evidence for post-synaptic expression of IL-31RA. The IL-31RA-immunoreactivity was concentrated in outer lamina II, corresponding to the most ventral distribution of TRPV1 terminals. As expected, i.t. injection of capsaicin - a neurotoxin that ablates central TRPV1 terminals 26, 27 - produced a significant loss of both TRPV1+ and IL-31RA+-immunoreactive terminals in the dorsal horn (Fig. 4e). Importantly, specificity of the IL-31RA antibody was demonstrated by the absence of IL-31RA immunoreactivity in DRG neurons obtained from IL-31RA KO mice (Supplementary Fig. 2). Thus, a small subset of unmyelinated peptidergic (TRPV1+) primary sensory neurons in DRG and TG express IL-31RA (Fig 4; Supplementary Fig. 3).
Neuronal mechanisms of IL-31-mediated itch

Previous studies in mice demonstrated that TRPV1- or TRPA1-expressing DRG neurons are important contributors to scratching behavior. Whether TRP channels are involved in IL-31-mediated itch is unknown. We found that i.t. capsaicin-treated mice markedly reduced IL-31-induced scratching (6.3 pmol/5 μl; 61±13.7 bouts/30 min in i.t. capsaicin-treated vs. 133.3±14.49 bouts/30 min in i.t. vehicle-treated mice (Fig. 5a). We next injected IL-31 (6.3 nmol/40 μl) into the nape of neck of TRPV1 KO mice, and observed a significant reduction of scratching bouts (47.75±2.56 bouts/30 min in TRPV1 KO vs. 140±23.97 bouts/30 min WT littermates; p=0.0086) (Fig. 5b). These findings demonstrate that TRPV1 is itself critical to IL31-evoked itch.

Because TRPA1 is required for Mas-related G protein-coupled receptor (Mrgpr)- and ET-1-mediated itch, we also studied the consequence of TRPA1 deletion. Figure 5c shows that there is a significant reduction of IL-31 (6.3 nmol/40 μl)-induced scratching, after nape of the neck injection, in TRPA1 KO mice (44.67±3.17 bouts/30 min vs. 139±11.86 bouts/30 min in WT littermates). To address the possibility that IL-31-evoked itch is amplified by a mast cell release of TRPV1/TRPA1-dependent pruritogens, e.g. histamine or tryptase, we injected IL-31 into the neck of mast-cell-deficient c-kit mutant and PAR-2 KO mice (6.3 nmol/40 μl). No differences were observed between c-kit mutant mice and their WT controls (142.8±6.48 bouts/30 min vs. 109±21.57 bouts/30 min, Fig. 5d). Also, we have not observed significant differences between PAR-2 KO (185.4±26.25 bouts/30 min) and WT littermate mice (154±20.59 bouts/30 min, Fig. 5e). Thus, IL-31-induced itch is independent of mast cell degranulation or PAR-2-mediated itch.

Functional characterization of IL-31-responsive DRG neurons

To identify the functional properties of the IL-31RA population of pruriceptors, we imaged cervical (C3–C8) DRG cells for their Ca\(^{2+}\)-responsiveness to IL-31 (Fig. 6). Consistent with the anatomical analysis, we found 2.1% (4/194) responded to 0.3 μM, 3.0% (32/1,054) to 1.0 μM, and 4.0% (4/100) to 3.0 μM IL-31 in a dose-responsive manner (Fig. 6a). A detailed analysis indicates heterogeneity in the responsiveness of DRG neurons: while some DRG neurons responded to IL-31 but not histamine, others responded to histamine but not IL-31 and others responded to both, or neither. Many IL-31-responsive cells responded to capsaicin, consistent with the predominant TRPV1 expression in IL-31-responsive neurons (Fig. 6a). Moreover, we found that 11.1% of 495 tested cells responded to histamine, 3.5% of 575 cells responded to SLIGRL, 8.3% of 484 cells responded to chloroquine, and 38.6% of 484 cells responded to AITC (mustard oil). Competence of viable cells was confirmed by a robust Ca\(^{2+}\)-influx detected in all cells exposed to capsaicin or high K\(^+\) (Fig. 6a). Thus, IL-31 induces robust Ca\(^{2+}\)-responses in DRG that are also inducible by agonists to TRPA1, TRPV1 and chloroquine.

Figure 6b and the Venn diagrams in Fig. 6c and d show the proportions of IL-31-responsive DRG compared to IL-31-responsive neurons that also responded to histamine, SLIGRL, chloroquine, capsaicin and AITC (Fig 6a and c). As compared to histamine (37.5%) and SLIGRL (21%), a higher percentage of IL-31-responsive cells were activated by capsaicin (67%) and AITC (91%), respectively (Fig. 6b and d). Finally, IL-31-responsive DRG neurons were significantly reduced in TRPV1- and TRPA1 KO animals (Fig. 6e). The percentage of IL-31-responsive DRG was significantly reduced in TRPV1 KO DRG and even more in TRPA1 KO DRG (Fig. 6e). Thus, in contrast to histamine or chloroquine, we show for the first time that IL-31-mediated calcium influx is, to some extent, dependent on TRPV1 and TRPA1 channels in murine DRG. As IL-31 did not elicit calcium responses in the absence of extracellular calcium, we conclude that IL-31 triggers influx of calcium through these TRP transduction channels.
Contribution of ERK1/2 to IL-31-mediated cell signaling in DRG neurons and IL31-provoked itch

Although MAPK signaling pathways have been implicated in the processing of pain message by primary afferents, their contribution to itch has not been studied. Figs. 7a and b show that IL-31 stimulation of cultured murine DRG neurons induced phosphorylation of ERK1/2 that peaked at 5 min. The MEK-inhibitor, U0126 completely prevented IL-31-mediated phosphorylation of ERK1/2 in vitro (Fig. 7c). By contrast, IL-31 was without effect on the p38 signaling pathways in DRG (Fig. 7d). Fig. 7e illustrates that i.p. injected U0126 (30 mg/kg) 30 min prior to IL-31 injection into neck (6.3 nmol/40 μl) significantly reduced scratching bouts (31.2±7.46 vs. 151.6±9.52 vehicle treated mice; p ≤0.0001). Thus, ERK1/2, but not p38, is required for IL-31-induced itch.

Neural responses to IL-31 in the dorsal horn of the spinal cord

To assess whether IL-31-induced itch activates pruritoceptive and/or nociceptive dorsal horn neurons, we used single unit extracellular recordings to define the properties of IL-31-activated dorsal horn neurons (Supplementary Fig. 4a-c). The majority of IL-31-responsive neurons was activated by pruritogens (histamine and SLIGRL) and noxious stimuli (heat and capsaicin; Supplementary Fig 4a and c). The fact that a common population of neurons responds to both itch- and pain-provoking stimuli suggests that a circuit downstream of the IL-31RA+/TRPV1+/TRPA1+ primary sensory neurons or a specific pattern of activity generated across subpopulations of responsive dorsal horn neurons determines the quality of the sensory perception (namely itch or pain).

Discussion

The resistance of prevalent pruritic diseases to anti-histamines, exemplified by AD, argues strongly for the existence of histamine-independent pruritic pathways that are important targets for therapy of chronic itch. We demonstrate that IL-31 induces itch by directly activating IL-31RA on TRPV1+/TRPA1+ sensory nerves in the skin. We show that TH2 cells are the predominant cellular source of IL-31, and that the number and activation of TH2 cells as well as IL-31 levels are increased in patients as well as in mouse models of AD. We conclude that TH2 cells are the source of a novel, IL-31 cytokine-triggered neuro-immune circuit that induces itch in TH2-dominated skin diseases by activating IL-31RA on sensory nerves. Whether the central terminals of primary afferents are targeted in pruritic diseases in which the blood-brain barrier is compromised, such as multiple sclerosis, allowing for penetration of IL-31 into the CNS, remains to be determined.

Other studies reported co-localization of OSMRβ, a receptor subunit targeted by IL-31, in the non-peptidergic, P2X3+ neuron population. In contrast, we found IL-31RA immunoreactivity predominantly in the peptidergic TRPV1/TRPA1+ neuron population (Fig. 4). Importantly, we confirmed specificity of our IL-31RA antibody by absence of immunostaining in IL-31RA KO mice (Fig. S2a). Intriguingly, while IL-31RA mRNA was
significantly increased in lesional skin of AD, this was not the case for OSMRβ mRNA indicating a pivotal role of IL-31RA but not OSMRβ in IL-31-mediated itch (Fig. 1a).

The fact that IL-31 injection into the cheek induced itch, but not pain, suggests that itch and pain are triggered by different subsets of unmyelinated afferents, and that subpopulations of afferents exist that are specialized in the itch domain. Indeed, single fiber recordings in humans described itch-specific unmyelinated afferents. We also found that chloroquine, which exerts its action via the MrgrpA3 subtype of the Mrgps activates a very large percentage (90%) of IL-31-responsive DRG neurons. Since we found that TRPA1 is also involved in IL-31-induced itch we conclude that the IL-31RA+/TRPV1+/TRPA1+ subset of DRG neurons is responsible for IL-31-induced itch. Future studies will determine whether IL-31 induces the release of BNP in murine central primary afferents or activates GRPR+ and/or NPR-A+ postsynaptic neurons.

Our electrophysiology analyses indicate that IL-31-responsive neurons in the dorsal horn can be activated by multiple pruritogens, which is consistent with a convergent itch transmission circuit. Furthermore, although some pruritogen-responsive dorsal horn neurons are activated by noxious stimuli, our finding that the central terminals of the IL-31RA+/TRPV1+ afferents target the outer part of lamina II, rather than lamina I, suggests that the postsynaptic neurons engaged by the IL31RA-expressing afferents are interneurons that are part of a circuit dedicated to itch. In this context, interneurons that express GRPR and/or NPR-A are ideally positioned to receive input from the IL-31RA+/ TRPV1+ afferents and presumably from the afferents that respond to other pruritogens. Together, we suggest that the IL-31RA+ population of afferents provides a major input that triggers itch, but not pain, and that GRPR+/NPR-A+ interneurons may be targets of these axons. Despite this apparent convergence, however, specificity of itch provoked by different pruritogens can be maintained because different pruritogens engage a variety of signaling pathways in the same neuron. The fact that itch or pain can be attenuated by inhibitors of ERK1/2 phosphorylation and our present findings is also consistent with convergence of itch and pain transmission, although the locus of the ERK1/2 action could differ in itch and pain-relevant circuits.

In conclusion, our results demonstrate that TH2-derived IL-31 directly communicates with an IL-31RA+/TRPV1+/TRPA1+ subpopulation of primary afferent neurons in the skin. We suggest that IL-31RA is a functional neural cytokine receptor involved in acute and chronic itch. In this respect, IL-31RA represents the long hypothesized “missing link” in a direct neuro-immune crosstalk between T cells and sensory nerves in itch. This finding emphasizes that not only mast cells via histamine or tryptase release, but also T cells via cytokines can directly communicate with sensory nerves to induce itch. Thus, blocking the effects of IL-31/IL-31RA may have a beneficial effect not only for the inhibition of inflammation but also to ameliorate directly the deleterious effects of T-cell-mediated itch. The exceptionally high incidence of itch and AD worldwide, and the fact that IL-31 as well as IL-31RA are elevated in both, underscores the significance of our findings for the development of IL-31-directed anti-pruritic therapies.

**Materials and Methods**

**Materials**

Recombinant mouse IL-31 was provided by ZymoGenetics, Inc. (Seattle, WA). For details, see Supplementary Material and Methods.
Patients

Patients and healthy controls were included after providing written informed consent within a study protocol approved by the ethics committees of the University Hospital Muenster, Heinrich-Heine-University Düsseldorf, and University Hospital Goettingen, Germany. For details, see Supplementary Material and Methods.

Purification of naive CD4+ T lymphocytes from adult blood and T helper cells

PBMCs were separated from buffy coats of healthy blood donor volunteers. For details, see Supplementary Material and Methods.

Cell isolation and cell culture of human cells

For details, see Supplementary Material and Methods.

Quantitative real time PCR (TaqMan®)

QPCR was performed to analyze expression of IL-31, IL31RA and OSMRβ in lesional vs. non-lesional skin from AD patients vs. healthy human subjects. For details, see Supplementary Materials and Methods.

Mouse model of AD and bacterial superantigen-induced skin inflammation

To determine IL-31 levels from AD-like skin lesions, we used two established mouse models, namely treatment with ovalbumin (OVA) or staphylococcus enterotoxin B (SEB), as described recently. For details, see Supplementary Materials and Methods.

Pruritogen-induced scratching

For details, see Supplementary Materials and Methods.

Immunostaining of mouse DRG and spinal cord

Cryosections of murine SC (10 μm) and DRGs (10 μm) were used. For details, see Supplementary Materials and Methods.

Primary DRG culture

Mice were anesthetized by intraperitoneal injection of pentobarbital, perfused transcardially with Ca2+-free and Mg2+-free PBS. DRG neurons were cultured, as previously described. For details, see Supplementary Materials and Methods.

Calcium imaging

Upper- to mid-cervical mouse DRGs were enzymatically digested and processed for calcium imaging as described. For details, see Supplementary Materials and Methods.

Western blotting

DRG neurons from primary cell culture were homogenized by hot lysis in protein lysis buffer containing a protease and phosphatases inhibitor mixture (Roche Applied Science, Penzberg, Germany) and sonicated. Then, cell debris was removed by centrifugation (14,000xg, 4°C, 10 min). Samples were processed as described. For details, see Supplementary Materials and Methods.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.
Acknowledgments

This work was supported by grants from the NIH/NIAMS (AR059402), Deutsche Forschungsgemeinschaft (DFG) (Ste1014/2-2), IZKF Muenster (STE3/034/07), CE.R.I.E.S. Paris (to M.S.); NIH NS14627 (to A.B.), NIH AR057194 (to E.C.); DFG Ce165/1-1 (to F.C.); DFG Ke1672/1-1 (to C.K.), DFG (Ho2092/4-1), DFG-FOR729 (Ho2092/5-2) (to B.H.). We thank Janine Bilsborough for helpful discussions, Mirela Iodi-Carstens for assistance in electrophysiology, Christine Stadelmann-Nesser for human DRG, Stephan Soeliger, Christian Mess, Ron Manlapaz, Robert Kubitz, Sabine Kellermann, Ulrike Wiesner, Ulrich Pippirs, Andrea Poppe, and Victoria Fong for expert technical assistance.

Non-standard abbreviations

C-kit/kit  white locus mutation (c-kit gene) resulting in mast-cell deficiency
CD45RO  isoform of leukocyte common form antigen
CLA   cutaneous lymphocyte-associated antigen
DAB  diaminobenzidine
DRG  dorsal root ganglia
EC  endothelial cells
ERK  extracellular signal-regulated kinases
ET-1   endothelin-1
Fb  fibroblast
h  hour
iDC  immature dendritic cell
IL  interleukin
IL-31RA  interleukin-31 receptor alpha
IB4  isolectin B4
i.t  intrathecal
KC  keratinocyte
KO  knockout
mDC  mature dendritic cell
ON  overnight
OSM Rβ  oncostatin M receptor-beta
OVA  ovalbumin
pERK1/2  phospho-ERK1/2
p-p38  phospho-p38
PBS  phosphate-buffered saline
qPCR  quantitative real time PCR
RT  room temperature
SC  spinal cord
SEB  staphylococcal enterotoxin B
TRG  trigeminal root ganglion
TRPA1 transient receptor channel potential cation channel ankyrin subtype-1
TRPV1 transient receptor potential cation channel vanilloid subtype-1
WT wild-type

References


37. Liu T, Ji RR. New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms? Pflugers Arch. 2013


Clinical Implications

We show that a functional cytokine receptor expressed by sensory nerves is involved in itch, leading to novel therapeutic strategies targeting neuronal cytokine receptors to treat T cell-mediated itch and atopic dermatitis.
Figure 1. IL-31 derives from human T\(_{H}2\) cells, and IL-31RA is expressed on human DRG neurons

(a) QPCR of IL-31, IL-31RAlong, IL-31RAshort, and OSMR-\(\beta\). (b) Co-localization of CLA (red) and IL-31 (green) in AD skin (scale bar = 100 \(\mu\)m). (c) Human T\(_{H}2\) cells express IL-31 mRNA. (d) Immature and mature dendritic cells (iDC/mDC) express IL-31 mRNA. (e) IL-31RA immunostaining in human DRG neurons (scale bar = 50 \(\mu\)m, (f) control). *P<0.05, **P<0.01, ***P<0.001, Mann-Whitney U test.
Figure 2. Superantigen-induced upregulation of IL-31 in AD-like mouse model

(a) Treatment regimen. (b) HE-staining of vehicle (PBS)- and SEB-treated skin (scale bar = 200 μm). Number of CD3+ T cells (c) and eosinophils (d) in vehicle- vs. SEB-treated skin. (e-f) qPCR from skin samples reveal increased mRNA levels for IL-31 (e) and IL-4 (f) in SEB-treated skin. N=8 mice/group. **p<0.01, ***p<0.001, Student’s t-test, error bars indicated as SEM.
Figure 3. *In vivo* effects of IL-31 in mice

(a) Injection of IL-31 into the nape of neck induced profound scratching. (b) Intraplantar IL-31 significantly increased paw-licking. (c) Cheek injection of IL-31 only produced scratching but no wiping (d). (e) Intrathecal injection of IL-31 induced significant dose-dependent scratching compared to vehicle. N=8 mice/group. **p<0.01, ***p<0.001, Student’s *t*-test, error bars indicated as SEM.
Figure 4. Localization of IL-31RA in murine DRG and spinal cord

(a) IL-31RA+ (red) and TRPV1+ (green) neurons partly co-localize. (b) Minimal overlap of IL-31RA (red) and IB4+ (green) subset of non-peptidergic nociceptors. (c) No overlap of IL-31RA+ (red) and N52+ unmyelinated neurons (green). (d) IL-31RA+/TRPV1+ in nerve terminals of the superficial dorsal horn. I.t. capsaicin (e), but not vehicle (d), ablated TRPV1+ (green) and IL-31RA (red) immunoreactivity. Scale bars = 100 μm.
Figure 5. Neuronal requirement of IL-31-induced itch
(a) Depletion of TRPV1+ neurons by i.t. capsaicin significantly decreased i.t. IL-31 induced scratching. (b) TRPV1KO and (c) TRPA1KO mice show reduction of IL-31 induced scratching compared to WT littermates. (d) c-Kit mutant mice and (e) PAR-2 KO mice showed equal scratching to WT mice after IL-31 injection. N=8 mice/group. **p<0.01, ***p<0.001, Student’s t-test, error bars indicated as SEM.
Figure 6. IL-31-induced calcium mobilization, and characterization of IL-31-responsive DRG neurons

(a) Neurons responding to IL-31 only (blue), histamine only (green), IL-31 and histamine (black), neither IL-31 nor histamine (red). (b) Percentages of IL-31-responsive neurons which also respond to other compounds. (c-d) Venn diagrams for DRG neurons in percentages. (e) Percentages of IL-31-responsive neurons in different KO mice. N=193-981 cells/group. For quantification, 10–30 dishes/group were used, and 20–50 cells/dish were counted. *p<0.05, **p<0.01, unpaired t-test, error bars indicated as SEM.
Figure 7. ERK1/2 phosphorylation in DRG is critical for IL-31-induced itch
(a) Western blot and (b) densitometry analysis of murine cultured DRG for pERK1/2 illustrate peak activation of ERK1/2 after 5 min. (c) Pre-treatment with the ERK1/2 inhibitor U0126 blocked IL-31-induced ERK1/2 activation. (d) IL-31 stimulation does not lead to p38-phosphorylation in cultured DRG. (e) I.p. injection of U0126 prior to IL-31 blocked IL-31-evoked scratching. N = 8 mice/group. p<0.001, Student’s t-test, error bars indicated as SEM.